Results 21 to 30 of about 2,411,306 (333)

Disease Knowledge Transfer across Neurodegenerative Diseases [PDF]

, 2019
We introduce Disease Knowledge Transfer (DKT), a novel technique for transferring biomarker information between related neurodegenerative diseases. DKT infers robust multimodal biomarker trajectories in rare neurodegenerative diseases even when only ...
Alexander, Daniel C., Blumberg, Stefano B., Crutch, Sebastian J., Eshaghi, Arman, Golland, Polina, Lorenzi, Marco, Marinescu, Razvan V., Morell, Pere P., Oxtoby, Neil P., Yong, Keir X., Young, Alexandra L.   +10 more
core   +4 more sources

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

Nucleic Acids Res., 2012
Alterations in cancer genomes strongly influence clinical responses to treatment and in many instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) is the largest public ...
Wanjuan Yang, Jorge Soares, Patricia Greninger, E. Edelman, H. Lightfoot, S. Forbes, Nidhi Bindal, D. Beare, James A. Smith, I. R. Thompson, Sridhar Ramaswamy, P. Futreal, D. Haber, M. Stratton, C. Benes, U. McDermott, M. Garnett   +16 more
semanticscholar   +1 more source

Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials

Clinical and Translational Medicine, 2014
Background Clinically useful biomarkers for patient stratification and monitoring of disease progression and drug response are in big demand in drug development and for addressing potential safety concerns.
Martin Letzkus, Evert Luesink, Sandrine Starck‐Schwertz, Marc Bigaud, Fareed Mirza, Nicole Hartmann, Bernhard Gerstmayer, Uwe Janssen, Andreas Scherer, Martin M Schumacher, Aurelie Verles, Alessandra Vitaliti, Nanguneri Nirmala, Keith J Johnson, Frank Staedtler   +14 more
doaj   +1 more source

Proteome Profiling of Diabetic Mellitus Patient Urine for Discovery of Biomarkers by Comprehensive MS-Based Proteomics

Proteomes, 2018
Diabetic mellitus (DM) is a disease that affects glucose homeostasis and causes complications, such as diabetic nephropathy (DN). For early diagnosis of DN, microalbuminuria is currently one of the most frequently used biomarkers.
Yoshitoshi Hirao, Suguru Saito, Hidehiko Fujinaka, Shigeru Miyazaki, Bo Xu, Ali F. Quadery, Amr Elguoshy, Keiko Yamamoto, Tadashi Yamamoto   +8 more
doaj   +1 more source

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]

, 2017
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger, Alcalay, Roy N., Babcock, Debra, Bowman, F. DuBois, Chen-Plotkin, Alice, David, Karen K., Dawson, Ted M., Dewey, Richard B., Jr., Foroud, Tatiana, German, Dwight, Gwinn, Katrina, Huang, Xuemei, Lungu, Codrin, Petyuk, Vlad, Potashkin, Judith A., Rosenthal, Liana S., Saunders-Pullman, Rachel, Scherzer, Clemens R., Sieber, Beth-Anne, St Hillaire-Clarke, Coryse, Sutherland, Margaret, Swanson-Fischer, Christine, Vaillancourt, David E., Walt, David R., West, Andrew B., Zhang, Jing   +25 more
core   +1 more source

Computational Models for Transplant Biomarker Discovery. [PDF]

, 2015
Translational medicine offers a rich promise for improved diagnostics and drug discovery for biomedical research in the field of transplantation, where continued unmet diagnostic and therapeutic needs persist.
Sarwal, Minnie M, Wang, Anyou
core   +2 more sources

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging

Nature Aging, 2022
Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems. Using the topographical information from [18F]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living ...
J. Therriault, T. Pascoal, F. Lussier, C. Tissot, M. Chamoun, G. Bezgin, S. Servaes, A. Benedet, N. Ashton, T. Karikari, J. Lantero‐Rodriguez, Peter Kunach, Y. Wang, J. Fernandez-Arias, G. Massarweh, P. Vitali, J. Soucy, P. Saha-Chaudhuri, K. Blennow, H. Zetterberg, S. Gauthier, P. Rosa-Neto   +21 more
semanticscholar   +1 more source

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]

, 2017
Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don, Brown-Swigart, Lamorna, Buxton, Meredith, DeMichele, Angela, Esserman, Laura, Glas, Annuska, Hirst, Gillian, Hylton, Nola, Linn, Sabine, Olopade, Olufunmilayo, Paoloni, Melissa, Petricoin, Emanuel, Rugo, Hope, Sanil, Ashish, Severson, Tesa M, Symmans, Fraser, van 't Veer, Laura, Wolf, Denise M, Wulfkuhle, Julia, Yau, Christina, Yee, Doug   +20 more
core   +2 more sources

Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

Cancer Discovery, 2020
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing-based estimates of TMB have largely replaced whole-exome sequencing-derived TMB in the ...
D. Sha, Zhaohui Jin, J. Budczies, K. Kluck, A. Stenzinger, F. Sinicrope   +5 more
semanticscholar   +1 more source

Stable Feature Selection for Biomarker Discovery [PDF]

, 2010
Feature selection techniques have been used as the workhorse in biomarker discovery applications for a long time. Surprisingly, the stability of feature selection with respect to sampling variations has long been under-considered.
He, Zengyou, Yu, Weichuan
core   +2 more sources